伊布替尼对比伊布替尼联合利妥昔单抗治疗慢性淋巴细胞白血病患者的随机试验
这项随机单中心试验将208例需治疗的慢性淋巴细胞白血病(CLL)患者分配至伊布替尼单药组(n=104)或伊布替尼联合利妥昔单抗组(n=104),中位随访36个月时两组无进展生存率分别为86%和86.9%,总缓解率均为92%;联合组外周血淋巴细胞计数正常化时间和完全缓解时间更短、骨髓残留病灶水平更低。作者结论认为联合利妥昔单抗未能改善无进展生存,伊布替尼单药仍是当前标准治疗。
要点
- 伊布替尼单药组与联合利妥昔单抗组的中位随访36个月无进展生存率分别为86%和86.9%。
- 两组总缓解率均为92%,联合组外周血淋巴细胞计数正常化时间和完全缓解时间更短。
- 联合组骨髓残留病灶水平更低,但作者结论认为加用利妥昔单抗未改善无进展生存。
核心结论
- 在复发性和初治高危CLL患者中,伊布替尼加用利妥昔单抗未能显示无进展生存改善。
- 接受伊布替尼联合利妥昔单抗的患者缓解更快且残留病灶水平显著更低。
- 基于这些结果,伊布替尼单药治疗仍是CLL当前的标准治疗。
研究设计与样本
- 随机单中心试验,比较伊布替尼单药与伊布替尼联合利妥昔单抗。
- 入组208例需治疗的CLL患者,其中181例复发CLL、27例初治高危(17p缺失或TP53突变)患者。
- 患者随机接受28天周期每日一次伊布替尼420 mg单药(n=104)或联合利妥昔单抗(375 mg/m2;n=104),利妥昔单抗第1周期每周给药,之后每周期一次至第6周期。
- 主要终点为意向治疗人群的无进展生存(PFS)。
- 试验注册号NCT02007044。
主要发现
- 中位随访36个月,伊布替尼组PFS的Kaplan-Meier估计值为86%(95%CI 76.6-91.9),伊布替尼联合利妥昔单抗组为86.9%(95%CI 77.3-92.6)。
- 两组总缓解率相同,均为92%。
- 伊布替尼联合利妥昔单抗组外周血淋巴细胞计数正常化时间和完全缓解时间更短,骨髓残留病灶水平更低。
临床怎么用
- 作者结论认为伊布替尼单药治疗仍是CLL当前的标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase, is an effective therapy for patients with chronic lymphocytic leukemia (CLL). To determine whether rituximab provides added benefit to ibrutinib, we conducted a randomized single-center trial of ibrutinib vs ibrutinib plus rituximab. Patients with CLL requiring therapy were randomized to receive 28-day cycles of once-daily ibrutinib 420 mg, either as a single agent (n = 104), or together with rituximab (375 mg/m2; n = 104), given weekly during cycle 1, then once per cycle until cycle 6. The primary end point was progression-free survival (PFS) in the intention-to-treat population. We enrolled 208 patients with CLL, 181 with relapsed CLL and 27 treatment-naive patients with high-risk disease (17p deletion or TP53 mutation). After a median follow-up of 36 months, the Kaplan-Meier estimates of PFS were 86% (95% confidence interval [CI], 76.6-91.9) for patients receiving ibrutinib, and 86.9% (95% CI, 77.3-92.6) for patients receiving ibrutinib plus rituximab. Similarly, response rates were the same in both arms (overall response rate, 92%). However, time to normalization of peripheral blood lymphocyte counts and time to complete remission were shorter, and residual disease levels in the bone marrow were lower, in patients receiving ibrutinib plus rituximab. We conclude that the addition of rituximab to ibrutinib in relapsed and treatment-naive high-risk patients with CLL failed to show improvement in PFS. However, patients treated with ibrutinib plus rituximab reached their remissions faster and achieved significantly lower residual disease levels. Given these results, ibrutinib as single-agent therapy remains current standard-of-care treatment in CLL. This trial was registered at www.clinicaltrials.gov as #NCT02007044.
引用
- Burger JA, Sivina M, Jain N, et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2018. PMID: 30530801. doi:10.1182/blood-2018-10-879429
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。